Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/120923
A child with resistant Kawasaki disease successfully treated with anakinra: a case report
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%. In spite of its effectiveness, some children do not respond to this therapy and still develop coronary aneurysms (CAA). The optimal treatment for IVIG non-responsive patients remains controversial although corticoids have been suggested to be an effective treatment in some patients. For those patients still resistant to IVIG and corticoids, interleukin-1 receptor antagonists (IL-1RA) such anakinra could be an alternative. Case presentation: We present a 3 year-old Caucasian patient with KD without cardiac complications but with important resistance to treatment. After becoming resistant to IVIG and corticoids, anakinra proved to be an effective treatment. Conclusions: To our knowledge, this is the first report of the utility of IL-1RA in refractory KD without coronary impairment. The patient fulfilled the classical criteria for KD and, after becoming resistant to first and second line treatments, anakinra proved to be an effective treatment. Further studies are required to determine if this is an effective treatment option for other cases of resistant Kawasaki disease.
Matèries
Matèries (anglès)
Citació
Citació
SÁNCHEZ MANUBENS, Judith, GELMAN, A., FRANCH, N., TEODORO, S., PALACIOS, J. r., RUDI, N., RIVERA, J., ANTÓN LÓPEZ, Jordi. A child with resistant Kawasaki disease successfully treated with anakinra: a case report. _BMC Pediatrics_. 2017. Vol. 17, núm. 102. [consulta: 23 de gener de 2026]. ISSN: 1471-2431. [Disponible a: https://hdl.handle.net/2445/120923]